Read by QxMD icon Read

Cannabis psychosis

James G Scott, Lori Matuschka, Solja Niemelä, Jouko Miettunen, Brett Emmerson, Antti Mustonen
There has been emerging evidence of an association between tobacco smoking and schizophrenia spectrum disorders (SSD). Two meta-analyses have reported that people who smoke tobacco have an ~2-fold increased risk of incident schizophrenia or psychosis, even after adjusting for confounding factors. This study aimed to critically appraise the research which has examined the association between tobacco smoking and SSD against the Bradford Hill criteria for causality, to determine the strength of the evidence for a causal relationship...
2018: Frontiers in Psychiatry
Anna Waterreus, Patsy Di Prinzio, Mathew T Martin-Iverson, Vera A Morgan
BACKGROUND: Growing evidence shows cannabis use is associated with lower rates of metabolic dysregulation. Despite cannabis impacting each sex differently, few studies have examined the metabolic profile of male and female cannabis users separately. Our aim was to investigate sex differences in the impact of cannabis use on metabolic syndrome in adults with psychotic illness. METHOD: Data from 1078 men and 735 women interviewed in the second Australian national survey of psychosis were analyzed using multiple logistic regression to model separately, for each sex, the influence of no, occasional and frequent past-year cannabis use on metabolic syndrome, adjusting for potential covariates including antipsychotic medication, smoking, and physical activity...
November 22, 2018: Drug and Alcohol Dependence
Marco Colizzi, Sagnik Bhattacharyya
The following chapter offers an overview of results of experimental studies conducted among healthy individuals examining the effects of acute administration of Δ9-THC and other cannabinoids, alone or in combination, on brain function and behavior, also as a function of previous cannabis exposure. In light of their methodological design, these studies have advanced the understanding of the neurobiological mechanisms increasing the risk of long-lasting cognitive dysfunction as well as psychosis in regular cannabis users...
2018: Progress in Brain Research
Melissa Hobbs, Nicola J Kalk, Paul D Morrison, James M Stone
Synthetic cannabinoid receptor agonists (SCRAs) are suggested to have increased potential to induce psychosis compared to natural cannabis (NC). In this review we synthesise current knowledge about the association of SCRA use with psychotic symptoms. Following a literature search we identified 2 toxicology reports, 4 case-control studies, 3 cross-sectional studies and 15 case reports. In each of the case reports, we identified the presence or absence of symptoms based on the items of the Postitive and Negative Syndrome Scele (PANSS)...
November 16, 2018: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
María Bettina Ortiz-Medina, Marta Perea, Julio Torales, Antonio Ventriglio, Giovanna Vitrani, Lourdes Aguilar, Carlos Roncero
OBJECTIVE: Cannabis consumption produces psychopathology, in some cases psychotic episodes, which are of our interest in this work. However, the relationship between cannabis use and psychosis has not been fully elucidated. The objectives of this work are to (1) review the current state of knowledge on the association of cannabis use with the risk of the development of psychosis or psychotic symptoms in people without schizophrenia and (2) assess the consistency of the hypothesis that cannabis use is associated with increased risk of psychosis in people without schizophrenia...
November 2018: International Journal of Social Psychiatry
Jacob Cookey, Candice E Crocker, Denise Bernier, Aaron J Newman, Sherry Stewart, David McAllindon, Philip G Tibbo
Accumulating evidence suggests that brain white matter (WM) abnormalities may be central to the pathophysiology of psychotic disorders. In addition, there is evidence that cannabis use and alcohol use each is associated with WM abnormalities. However, there are very limited data on the effects of these substances on WM microstructure in patients with psychosis, especially for those at the early phase of illness. This project aimed to examine the impact of cannabis use and alcohol use on WM tissue in early-phase psychosis (EPP)...
November 2018: Brain Connectivity
Shera Hosseini, Mark Oremus
OBJECTIVES: This study was conducted to review the current state of evidence on the association between age of initiation of cannabis use and symptoms of psychosis, depression, or anxiety among youth under 25 years of age. METHODS: We conducted a systematic review of articles published prior to March 2018 by searching OVID MEDLINE, PsycINFO, EMBASE, and the references of included studies. We included comparative studies (cohort, case-control, cross-sectional) that reported on cannabis use in persons <25 years of age (exposure) and symptoms of psychosis, depression, or anxiety (outcome)...
October 29, 2018: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
Michael A P Bloomfield, Chandni Hindocha, Sebastian F Green, Matthew B Wall, Rachel Lees, Katherine Petrilli, Harry Costello, M Olabisi Ogunbiyi, Matthijs G Bossong, Tom P Freeman
The laws governing cannabis are evolving worldwide and associated with changing patterns of use. The main psychoactive drug in cannabis is Δ9 -tetrahydrocannabinol (THC), a partial agonist at the endocannabinoid CB1 receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems...
October 19, 2018: Pharmacology & Therapeutics
F Schürhoff, G Fond, F Berna, E Bulzacka, O Godin, L Boyer, D Misdrahi, M Andrianarisoa, L Brunel, N Coulon, B Aouizerate, D Capdevielle, I Chereau, T D'Amato, C Dubertret, J Dubreucq, C Faget, F Gabayet, J Mallet, R Rey, C Lancon, C Passerieux, A Schandrin, M Urbach, P Vidailhet, M Leboyer, P M Llorca
OBJECTIVES: The present article is a synthesis of the first 10 years of follow-up of the FondaMental Academic Center of Expertise for Schizophrenia (FACE-SZ) cohort. METHODS: More than 700 community-dwelling stabilized subjects have been recruited and evaluated to date. The mean age was 32 years with 75 % males, the mean illness duration was 11 years, the mean age at illness onset was 21 years, the mean duration of untreated psychosis was 1.5 years and 55 % were current daily tobacco smokers...
October 13, 2018: L'Encéphale
Jacqueline Mayoral-van Son, María Juncal-Ruiz, Víctor Ortiz-García de la Foz, David Cantarero-Prieto, Carla Blázquez-Fernández, María Paz-Zulueta, Paula Paras-Bravo, José L Ayuso-Mateos, Benedicto Crespo-Facorro
AIM: Early intervention psychiatric services for patients with psychosis aim to limit the most damaging outcomes and reduce the patient's risk of social drift, decreasing illness severity and thus containing healthcare costs. There is a scarcity of studies that focus on first-episode psychosis (FEP), and those few that have been published only looked at direct health costs, but not at indirect costs, which make up the bulk of the budget. Our study aims to explore the short-term (1-year follow-up) economic cost of a FEP Program, including both direct and indirect costs...
October 12, 2018: Early Intervention in Psychiatry
Rasmon Kalayasiri, Korakot Kraijak, Michael Maes, Apiwat Mutirangura
The use of psychoactive substances, including methamphetamine (MA) may cause changes in DNA methylation. The aim of this study was to examine the effects of MA use on long interspersed element-1 (LINE-1) methylation patterns in association with MA-induced paranoia. This study recruited 123 normal controls and 974 MA users, 302 with and 672 without MA-induced paranoia. The Semi-Structured Assessment for Drug Dependence and Alcoholism was used to assess demographic and substance use variables. Patterns of LINE-1 methylation were assessed in peripheral blood mononuclear cells and a combined bisulfite restriction analysis (COBRA) was used to estimate overall LINE-1 methylation (mC) while COBRA classified LINE-alleles into four patterns based on the methylation status of two CpG dinucleotides on each strand from 5' to 3', namely two methylated (mCmC) and two unmethylated (uCuC) CpGs and two types of partially methylated loci (mCuC that is 5'm with 3'u and uCmC that is 5'u with 3'm CpGs)...
October 9, 2018: Molecular Neurobiology
Avner Thaler, Shira Arad, Lihi Bar-Lev Schleider, Judith Knaani, Tali Taichman, Nir Giladi, Tanya Gurevich
INTRODUCTION: Patients with Gilles de la Tourette syndrome (GTS) experience reduced function and impaired quality of life. The current medical treatments for this syndrome can cause significant side effects and offer partial symptomatic relief. In a few small trials medical cannabis (MC) has been suggested to offer symptomatic relief with a relatively benign side effect profile. We conducted a real-life assessment of clinical benefit and adverse effects of chronic MC treatment among patients with GTS...
October 1, 2018: Parkinsonism & related Disorders
Jasmina Mallet, Nicolas Mazer, Caroline Dubertret, Yann Le Strat
OBJECTIVE: Recent findings suggest an association between tobacco and psychosis, but whether this association is mediated by confounding factors is unknown. Psychosis-like experiences (PLEs) are a subclinical expression of psychosis. To disentangle the association of tobacco with PLEs, we examined data from a large US population-based, nationally representative sample. METHODS: Analysis was conducted on Wave 2 of the National Epidemiologic Survey of Alcohol and Related Conditions (N = 34,653 adults, conducted from 2004 to 2005)...
October 2, 2018: Journal of Clinical Psychiatry
Rajiv Radhakrishnan, Sinan Guloksuz, Margreet Ten Have, Ron de Graaf, Saskia van Dorsselaer, Nicole Gunther, Christian Rauschenberg, Ulrich Reininghaus, Lotta-Katrin Pries, Maarten Bak, Jim van Os
BACKGROUND: Evidence suggests that cannabis use, childhood adversity, and urbanicity, in interaction with proxy measures of genetic risk, may facilitate onset of psychosis in the sense of early affective dysregulation becoming 'complicated' by, first, attenuated psychosis and, eventually, full-blown psychotic symptoms. METHODS: Data were derived from three waves of the second Netherlands Mental Health Survey and Incidence Study (NEMESIS-2). The impact of environmental risk factors (cannabis use, childhood adversity, and urbanicity) was analyzed across severity levels of psychopathology defined by the degree to which affective dysregulation was 'complicated' by low-grade psychotic experiences ('attenuated psychosis' - moderately severe) and, overt psychotic symptoms leading to help-seeking ('clinical psychosis' - most severe)...
October 4, 2018: Psychological Medicine
Bonnie J Leadbeater, Megan E Ames, Ashley N Linden-Carmichael
AIMS: We tested the age-varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested. DESIGN: Time-varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis, depression and anxiety at each age. SETTING AND PARTICIPANTS: Adolescent data (V-HYS; n = 662) were collected from a randomly recruited sample of adolescents in Victoria, British Columbia, Canada during a 10-year period (2003-13)...
October 1, 2018: Addiction
Lauren E Reeves, Brandon A Gaudiano, Jane Metrik, Carolina Guzman Holst, Alexandra Morena, Valerie J Sydnor, Lauren M Weinstock, Gary Epstein-Lubow
OBJECTIVE: Individuals with psychotic-spectrum disorders use tobacco and cannabis at higher rates than the general population and individuals with other psychiatric disorders, which may contribute to increased rates of medical problems and mortality. The present study examined whether individuals with psychosis and comorbid tobacco and/or cannabis use disorders exhibit differing clinical characteristics in terms of their sociodemographic, mental health, substance use, physical health, and medication use patterns...
September 28, 2018: Journal of Dual Diagnosis
Rohit J Lodhi, Yabing Wang, David Rossolatos, Georgina MacIntyre, Alexandra Bowker, Candice Crocker, Hongyan Ren, Aleksandra Dimitrijevic, Darren A Bugbee, Alexandra Loverock, Brett Majeau, Sudhakar Sivapalan, Virginia M Newton, Philip Tibbo, Scot E Purdon, Katherine J Aitchison
No abstract text is available yet for this article.
September 2018: Brain and Behavior
Sellwane M Mere, Saeeda Paruk
Background: Comorbid human immunodeficiency virus (HIV) infection among patients with psychotic disorders is associated with a poorer outcome. Understanding the association of HIV infection with demographic and clinical variables may provide clues to modify risk factors and outcomes. Aim: To describe and compare the socio-demographic and clinical profile of patients admitted with psychotic disorders with and without HIV infection. Method: A retrospective chart review of 100 adult patients consecutively admitted with psychosis and HIV infection and compared to 101 patients with psychosis without HIV infection...
2018: South African Journal of Psychiatry: SAJP: the Journal of the Society of Psychiatrists of South Africa
Kazunori Matsumoto, Masahiro Katsura, Naohisa Tsujino, Shimako Nishiyama, Takahiro Nemoto, Naoyuki Katagiri, Tsutomu Takahashi, Yuko Higuchi, Noriyuki Ohmuro, Hiroo Matsuoka, Michio Suzuki, Masafumi Mizuno
There has been recent accumulation of evidence and clinical guidance regarding the at-risk mental state (ARMS) for psychosis. However, most studies have been observational cohort and intervention studies of Western populations. To assess the validity of the ARMS concept and the transition rate to psychosis in a non-Western nation, we retrospectively combined and analyzed clinical data of individuals diagnosed with ARMS who were prospectively followed-up at three specialized clinical services for ARMS in Japan...
September 12, 2018: Schizophrenia Research
Lauren Hood
Cannabis, or the dried leaves, stems, and seeds of the hemp plant Cannabis sativa, is the most widely used illicit drug in America. Typically smoked, vaporized or ingested orally, cannabis is used primarily for recreational purposes, though a few synthetic cannabinoids have been approved for medicinal treatments. Psychoactive cannabinoids, or the pharmacologically active compounds within cannabis, are responsible for producing the infamous "high" sensation, characterized by feelings of euphoria and relaxation, though can also provoke hallucinations, paranoia and anxiety...
2018: International Review of Neurobiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"